Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alnylam Pharmaceut (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,911,655
  • Shares Outstanding, K 100,670
  • Annual Sales, $ 89,910 K
  • Annual Income, $ -490,870 K
  • 36-Month Beta 2.55
  • Price/Sales 87.99
  • Price/Cash Flow N/A
  • Price/Book 4.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -2.03
  • Number of Estimates 4
  • High Estimate -1.86
  • Low Estimate -2.21
  • Prior Year -1.34
  • Growth Rate Est. (year over year) -51.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.29 +0.47%
on 10/19/18
96.14 -20.27%
on 09/20/18
-18.17 (-19.16%)
since 09/19/18
3-Month
76.29 +0.47%
on 10/19/18
124.21 -38.29%
on 08/31/18
-29.61 (-27.87%)
since 07/19/18
52-Week
76.29 +0.47%
on 10/19/18
153.99 -50.22%
on 03/20/18
-38.98 (-33.71%)
since 10/19/17

Most Recent Stories

More News
INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 19, 2018 / , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the...

ALNY : 76.65 (-2.47%)
SHAREHOLDER ALERT: LOGM SKX PVG USAT ALNY MGTI HAS HTHT GOOG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

PVG : 7.98 (-1.12%)
SKX : 29.72 (+13.78%)
GOOG : 1,096.46 (+0.78%)
USAT : 5.94 (-2.78%)
ALNY : 76.65 (-2.47%)
HTHT : 28.16 (+1.40%)
LOGM : 81.03 (-1.13%)
MGTI : 0.0549 (-12.86%)
HAS : 98.04 (-0.46%)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline - November 26, 2018

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY)...

ALNY : 76.65 (-2.47%)
IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 18, 2018 / , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the...

ALNY : 76.65 (-2.47%)
CLASS ACTION UPDATE for PZZA, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

PZZA : 52.44 (-1.83%)
ALNY : 76.65 (-2.47%)
CHGG : 25.26 (-1.98%)
Alnylam Pharmace Shares Down 26.9% Since SmarTrend's Sell Call (ALNY)

SmarTrend identified a Downtrend for Alnylam Pharmace (NASDAQ:ALNY) on September 7th, 2018 at $111.15. In approximately 1 month, Alnylam Pharmace has returned 26.89% as of today's recent price of $81.26....

ALNY : 76.65 (-2.47%)
SHAREHOLDER ALERT: TRCO MCHP ALNY MGTI CPB CHGG ADNT TRVN SFIX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

TRVN : 0.82 (-4.65%)
CPB : 37.93 (+3.44%)
SFIX : 24.16 (-5.85%)
ADNT : 30.19 (+1.58%)
ALNY : 76.65 (-2.47%)
MCHP : 67.03 (-0.77%)
CHGG : 25.26 (-1.98%)
MGTI : 0.0549 (-12.86%)
TRCO : 38.81 (+0.28%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY

NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (''Alnylam'' or the ''Company'') (NASDAQ: ALNY)...

ALNY : 76.65 (-2.47%)
Alnylam to Pursue Full Approval & Rolling NDA for Givosiran

Alnylam (ALNY) plans to pursue a full approval of givosiran and submit rolling new drug application (NDA) for the same.

MDCO : 26.90 (-1.25%)
ALNY : 76.65 (-2.47%)
NVS : 87.19 (+1.10%)
RHHBY : 30.5950 (+2.55%)
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 15, 2018 / , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the...

ALNY : 76.65 (-2.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ALNY with:

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 81.07
1st Resistance Point 78.86
Last Price 76.65
1st Support Level 75.37
2nd Support Level 74.08

See More

52-Week High 153.99
Fibonacci 61.8% 124.31
Fibonacci 50% 115.14
Fibonacci 38.2% 105.97
Last Price 76.65
52-Week Low 76.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar